EZZ Life Science Holdings Limited (EZZ.AX)

EZZ Life Science Holdings Limited (EZZ.AX) — VMCI valuation read

EZZ Life Science Holdings Limited (EZZ.AX) carries a VMCI composite of 69/100, 19 points above the Healthcare sector median of 50. Among mid-cap names, that gap places EZZ.AX in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The EZZ.AX insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads EZZ.AX trades at 24.0x earnings, 33% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 1.0x leaves covenant headroom, the line to track on EZZ Life Science Holdings Limited's next 10-Q.

EZZ.AX rose 0.7% over the trailing 7 days, with a +7.8% read on a 30-day basis.